TABLE 3.
Pooled risk estimates of safety outcomes from randomized controlled trials of therapy against invasive fungal infection
| Drug(s) | No. of trial arms included | Total no. of patients included | % of patients with: |
|||||
|---|---|---|---|---|---|---|---|---|
| Treatment discontinuation due to adverse effects |
Elevation of liver enzyme levels requiring stopping of treatment |
Elevation of liver enzyme levels not requiring stopping of treatment |
||||||
| Pooled estimate | 95% CI | Pooled estimate | 95% CI | Pooled estimate | 95% CI | |||
| Amphotericin B formulationsa | 41 | 4,775 | 13.4 | 8.9-17.8 | 0.4 | 0.1-0.8 | 14.1 | 10.3-18.0 |
| Itraconazole | 3 | 293 | 18.8 | 14.3-23.2 | 1.5 | 0-4.0 | 17.4 | 3.9-31.0 |
| Fluconazole | 10 | 697 | 2.2 | 0-4.6 | 0.7 | 0-1.4 | 9.3 | 4.0-14.5 |
| Voriconazole | 3 | 881 | 9.5 | 2.3-16.8 | NAb | NA | 19.7 | 16.8-22.6 |
| Anidulafungin | 4 | 251 | 8.4 | 3.6-13.1 | 0.8 | 0-2.3 | 2.0 | 0.3-3.7 |
| Caspofungin | 5 | 1,075 | 3.8 | 2.7-5.0 | 0.2c | 0.1-0.4c | 7.0 | 4.1-9.9 |
| Micafungin | 3 | 666 | 3.6 | 2.2-5.0 | 2.7 | 0.7-4.6 | 3.0 | 1.0-5.1 |
a
Including amphotericin B desoxycholate, amphotericin B colloidal dispersion, amphotericin B lipid complex, and liposomal amphotericin B.
b
NA, not available.
c
Adjusted Wald method for point estimate and confidence interval.